Stocks · News reference
Haemonetics stock hits a new 52-week high after CSL Plasma outlines a sweeping rollout of its technology across existing U.S. centers.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Haemonetics (NYSE:HAE) reported second-quarter financial results on Thursday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
Haemonetics Corporation released its financial results for the second quarter of fiscal year 2027, covering the period ended September 26, 2026.
Filed: 2026-11-05 AccNo: 0000313143-26-000150 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months. The company, which provides blood management systems, is positioned in the top 20% of Zacks-covered stocks based on estimate revisions, suggesting potential near-term stock price appreciation.
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $118 to $140.